The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling.
immune checkpoints
immunophenotyping
metastatic niche
oesophageal adenocarcinoma
prognostic
tumour-draining lymph node
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Aug 2021
09 Aug 2021
Historique:
received:
24
05
2021
revised:
24
07
2021
accepted:
04
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Response rates to the current gold standards of care for treating oesophageal adenocarcinoma (OAC) remain modest with 15-25% of patients achieving meaningful pathological responses, highlighting the need for novel therapeutic strategies. This study consists of immune, angiogenic, and inflammatory profiling of the tumour microenvironment (TME) and lymph node microenvironment (LNME) in OAC. The prognostic value of nodal involvement and clinicopathological features was compared using a retrospective cohort of OAC patients (
Identifiants
pubmed: 34439160
pii: cancers13164005
doi: 10.3390/cancers13164005
pmc: PMC8391676
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Immunol Res. 2017 Nov;5(11):969-977
pubmed: 28935649
J Immunother Cancer. 2019 May 22;7(1):133
pubmed: 31118093
Science. 2001 Jul 13;293(5528):293-7
pubmed: 11452123
Ann Surg. 2013 Nov;258(5):784-92; discussion 792
pubmed: 24045450
Ann Surg. 2014 Nov;260(5):779-84; discussion 784-5
pubmed: 25379849
Br J Surg. 2017 Dec;104(13):1816-1828
pubmed: 28944954
Blood. 2011 Sep 1;118(9):2502-10
pubmed: 21750314
Cancer Immunol Immunother. 2003 Oct;52(10):617-24
pubmed: 12802519
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
Front Immunol. 2014 Jun 17;5:276
pubmed: 24987392
Clin Cancer Res. 2005 Nov 1;11(21):7683-91
pubmed: 16278388
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Ann Thorac Surg. 2006 Aug;82(2):480-4; discussion 484-5
pubmed: 16863749
Cell Immunol. 2012;272(2):166-74
pubmed: 22082565
Cancer Lett. 2021 Apr 1;502:84-96
pubmed: 33450360
Nat Commun. 2018 May 29;9(1):2113
pubmed: 29844317
Cancer Immunol Immunother. 2019 Oct;68(10):1681-1688
pubmed: 30944963
N Engl J Med. 1998 Dec 31;339(27):1979-84
pubmed: 9869669
J Clin Oncol. 2018 Jan 1;36(1):61-67
pubmed: 29116900
Ann Surg Oncol. 2016 Dec;23(Suppl 5):998-1004
pubmed: 27480358
Anticancer Res. 2018 Feb;38(2):893-900
pubmed: 29374717
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E761-E770
pubmed: 28096382
Ann Surg Oncol. 2008 Oct;15(10):2894-902
pubmed: 18663531
Science. 2018 Mar 23;359(6382):1403-1407
pubmed: 29567713
Clin Cancer Res. 2018 Oct 15;24(20):5058-5071
pubmed: 29898992
World J Gastroenterol. 2013 Dec 28;19(48):9282-93
pubmed: 24409055
Ann Surg. 2008 Feb;247(2):365-71
pubmed: 18216546
PLoS One. 2013;8(1):e53798
pubmed: 23365642
Ann Surg. 2020 Nov;272(5):814-819
pubmed: 32657924
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Ann Surg. 1907 Jul;46(1):1-19
pubmed: 17861990
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):298-313
pubmed: 32005946
Front Oncol. 2020 Jun 04;10:891
pubmed: 32582553
Science. 2018 Mar 23;359(6382):1408-1411
pubmed: 29567714
Ann Surg. 2017 Jan;265(1):122-129
pubmed: 28009736
Cancer Immunol Immunother. 2018 Jan;67(1):47-60
pubmed: 28905118
Ann Surg. 2008 Oct;248(4):549-56
pubmed: 18936567
Cancer Immunol Res. 2015 Jan;3(1):48-58
pubmed: 25361854
Int J Mol Sci. 2021 Jan 22;22(3):
pubmed: 33499003
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Ann Surg. 2017 Feb;265(2):356-362
pubmed: 28059964
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518694
Br J Surg. 2020 Jul;107(8):1042-1052
pubmed: 31997313
Cancers (Basel). 2020 Nov 13;12(11):
pubmed: 33202734
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936